Contrast-Induced Acute Kidney Injury
12
2
2
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
8.3%
1 terminated out of 12 trials
85.7%
-0.8% vs benchmark
8%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
Predictors of Contrast-induced Acute Renal Injury in Patients With Acute Coronary Syndrome
ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
Remote Ischemic Preconditioning to Prevent Contrast-Induced Kidney Injury in Diabetic Patients (PRINCES)
Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury
A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI
DyeVert System and Contrast-induced Acute Kidney Injury
The Role of Statins in the Prevention of Contrast-induced Acute Kidney Injury in Patients With Cardiovascular Diseases
A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI
Effect of Allopurinol or Febuxostat to Prevent Contrast Induced Acute Kidney Injury (CI-AKI)
Microalbuminuria Predicting CIAKI After CAG
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury